Core Insights - Zomedica will review its 2025 financial results and discuss opportunities in the equine veterinary market during an investor webinar on March 27, 2026 [1][2] - The equine industry contributes approximately $122 billion annually to the U.S. economy, highlighting a significant market opportunity for veterinary care [1] - The global equine population is estimated to exceed 60 million horses, indicating a substantial demand for veterinary services [1] Financial Performance - Zomedica reported an 8% revenue growth in 2024, reaching $27 million, and maintains a strong liquidity position of approximately $54.4 million as of September 30, 2025 [2] - The company aims to enhance revenue opportunities while moving towards sustained profitability [1][2] Market Opportunity - The equine veterinary services market represents a multi-billion-dollar opportunity, driven by increasing investment in sport horse medicine and advanced therapeutic technologies [1] - Annual care and training expenses for sport horses can range from $25,000 to over $100,000, depending on the discipline, further emphasizing the market potential [1] - The global veterinary diagnostics market is projected to exceed $10 billion by the end of the decade, with equine diagnostics being a specialized segment within this market [1] Product Portfolio - Zomedica's product offerings include the TRUFORMA® diagnostic platform, PulseVet® shock wave therapy, Assisi EquiLoop™ device, TRUVIEW® digital cytology, and VETIGEL® hemostatic gel, all designed to support veterinary practices [1][2] - The company focuses on addressing key clinical needs in equine medicine, particularly in endocrine diagnostics and metabolic disorders [1]

Company Overview - Zomedica Corp. is a veterinary health company focused on point-of-care diagnostic and therapeutic products for equine and companion animals [3] - The company offers a range of innovative solutions including the PulseVet® shock wave system, Assisi® Loop therapeutic devices, TRUFORMA® diagnostic platform, TRUVIEW® digital cytology system, VETGuardian® monitoring system, and VETIGEL® hemostatic gel [3] - Zomedica's total addressable market in the U.S. exceeds $2 billion [3] - The company is headquartered in Michigan and employs approximately 150 people, with manufacturing and distribution facilities in Georgia and Minnesota [3] Financial Performance - Zomedica reported an 8% revenue growth in 2024, reaching $27 million [3] - As of March 31, 2025, the company maintains a strong balance sheet with approximately $65 million in liquidity [3] Strategic Initiatives - Zomedica is advancing its product offerings through strategic acquisitions and international expansion [3] - The company aims to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow, and profitability of veterinary practices [3] Upcoming Events - Larry Heaton, CEO of Zomedica, will present at the OTCQB Venture Virtual Investor Conference on August 7, 2025, at 1:30 PM ET [1] - The event will allow real-time interaction with investors, and an archived webcast will be available post-event [1]